Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (15 items missing)
No data available for the selected time periods
in million USD FY '08FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Net sales
1,764
1,784
1,927
2,074
2,069
2,133
2,175
2,019
Cost of goods sold
802
784
836
895
914
954
997
898
Gross Profit
963
1,000
1,091
1,179
1,155
1,178
1,179
1,122
Selling, general and administrative expense
591
601
635
696
682
798
808
762
Research and development expense
160
164
172
178
209
211
220
193
Impairment loss on long-lived assets
29
4
0
0
0
0
0
0
Income from operations
183
231
284
305
264
169
150
167
Interest expense
32
47
64
53
51
61
22
22
Foreign exchange losses, net
8
5
4
14
5
9
9
10
Other (income) expense, net
0
-7
-4
-8
-22
-13
-13
-11
Income before income taxes
143
186
220
246
230
112
132
146
Provision for income taxes
45
-37
-33
-67
-64
-35
-43
-33
Net income including noncontrolling interests
98
149
187
179
166
78
89
113
Net loss (income) attributable to noncontrolling interests
9
-5
-1
0
0
0
0
0
Net income attributable to Bio-Rad
90
145
185
179
165
78
89
113
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Mar 18, 2013 n/a
calculated values,
restated on Mar 18, 2014 n/a
calculated values,
restated on Mar 2, 2015 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (52 items missing)
No data available for the selected time periods
in million USD FY '08FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash and cash equivalents
n/a
650
907
574
463
332
413
458
Restricted cash
n/a
0
6
0
0
0
0
0
Short-term investments
n/a
95
119
239
458
277
284
329
Restricted investments
n/a
0
0
0
0
0
0
4
Accounts receivable, less allowance for doubtful accounts
n/a
346
388
399
399
423
378
391
Raw materials
n/a
68
82
99
93
106
106
110
Work in Process
n/a
98
111
120
125
130
132
114
Finished Goods
n/a
186
205
214
237
281
233
266
Total Inventories
n/a
351
398
434
455
516
471
490
Deferred tax assets
n/a
43
48
54
0
0
0
0
Prepaid expenses
n/a
0
0
0
92
131
108
0
Other current assets
n/a
78
110
99
69
79
62
105
Total current assets
n/a
1,563
1,975
1,798
1,937
1,757
1,716
1,778
Land and improvements
n/a
17
18
19
19
19
18
0
Buildings and leasehold improvements
n/a
205
233
250
268
284
283
0
Equipment
n/a
507
561
613
725
756
788
0
Total property, plant and equipment
n/a
728
812
882
1,012
1,060
1,089
1,117
Less: accumulated depreciation and amortization
n/a
-426
-479
-532
-595
-645
-660
-679
Property, plant and equipment, net
n/a
302
334
350
417
414
429
438
Goodwill, net
n/a
328
364
469
495
518
500
496
Long-term deferred tax assets
n/a
13
13
11
0
0
0
0
Purchased intangibles, net
n/a
205
204
259
261
266
254
214
Other investments
n/a
0
0
0
294
378
389
720
Other assets
n/a
125
173
210
40
55
52
65
Total assets
n/a
2,536
3,063
3,097
3,444
3,389
3,341
3,710
Liabilities and owners' equity
Accounts payable
n/a
93 92988000
113 113440000
129 129124000
131 130867000
149 148510000
129 128608000
0 0
Accrued payroll and employee benefits
n/a
127 126702000
131 131381000
113 112564000
136 135955000
131 130658000
153 153426000
280 280248000
Current maturities of long-term debt
n/a
5 5132000
233 233181000
1 814000
2 1750000
2 1786000
0 265000
0 298000
Income and other taxes payable
n/a
42 42322000
51 50935000
52 52285000
35 34779000
34 33555000
35 35165000
29 29339000
Accrued royalties
n/a
47 46692000
24 23944000
25 25219000
30 29718000
0 0
0 0
0 0
Deferred revenue
n/a
0 0
21 20642000
24 24322000
26 26288000
26 26390000
27 26716000
0 0
Estimated loss contingency
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Accrued legal settlements
n/a
0 0
0 0
0 0
0 0
30 30000000
0 0
0 0
Other current liabilities
n/a
106 106136000
93 93104000
115 114787000
113 113043000
117 116573000
103 102581000
131 131466000
Total current liabilities
n/a
420 419972000
667 666627000
459 459115000
472 472400000
487 487472000
447 446761000
441 441351000
Long-term debt, net of current maturities
n/a
738 737919000
731 731100000
732 731698000
732 732414000
436 435615000
436 435710000
434 433883000
Deferred income taxes
n/a
43 42894000
60 59738000
86 85522000
115 115054000
162 162110000
155 154917000
0 0
Other long-term liabilities
n/a
56 55855000
65 64780000
76 76086000
108 108095000
117 116871000
119 118735000
344 343981000
Total liabilities
n/a
1,257 1256640000
1,522 1522245000
1,352 1352421000
1,428 1427963000
1,202 1202068000
1,156 1156123000
1,219 1219215000
Commitments and contingent liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Preferred stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Common stock
n/a
0 2000
0 0
0 0
0 0
0 0
0 0
0 0
Class B common stock
n/a
0 1000
0 0
0 0
0 0
0 0
0 0
0 0
Additional paid-in capital
n/a
130 130444000
157 156986000
185 185334000
212 212244000
240 239986000
271 271346000
300 300408000
Retained earnings
n/a
996 996197000
1,182 1181687000
1,360 1359910000
1,528 1528327000
1,606 1606117000
1,695 1694962000
1,808 1808055000
Accumulated other comprehensive income
n/a
133 133082000
198 198020000
199 198690000
275 274532000
341 340717000
219 218945000
382 382138000
Total stockholders' equity
n/a
1,260 1259726000
1,537 1536696000
1,744 1743937000
2,015 2015005000
2,187 2186722000
2,185 2185155000
2,491 2490503000
Noncontrolling interests
n/a
19 19487000
4 3823000
0 445000
1 535000
0 0
0 0
0 0
Total stockholders' equity
n/a
1,279 1279213000
1,541 1540519000
1,744 1744382000
2,016 2015540000
0 0
0 0
0 0
Total liabilities and stockholders' equity
n/a
2,536 2535853000
3,063 3062764000
3,097 3096803000
3,444 3443503000
3,389 3388790000
3,341 3341278000
3,710 3709718000
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Feb 29, 2012 n/a restated on Nov 30, -1 n/a restated on Mar 18, 2014 n/a restated on Mar 2, 2015 n/a restated on Nov 30, -1 n/a restated on Aug 5, 2016 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (40 items missing)
No data available for the selected time periods
in million USD FY '08FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Cash received from customers
1,766
1,778
1,877
2,019
2,064
2,090
2,163
1,956
Cash paid to suppliers and employees
-1,496
-1,386
-1,537
-1,640
-1,664
-1,804
-1,807
-1,730
Interest paid
-31
-38
-60
-57
-46
-61
-21
-21
Income tax payments
-49
-38
-56
-69
-94
-71
-29
-32
Settlement with the SEC and DOJ relating to the FCPA, including interest
0
0
0
0
0
0
-55
0
Investment proceeds and miscellaneous receipts, net
6
10
4
10
13
17
16
12
Excess Tax Benefits from Share-based Compensation
-5
-1
-3
-3
-3
-3
-1
-4
Proceeds from forward foreign exchange contracts, net
-5
-3
3
3
-3
1
8
4
Net cash provided by operating activities
191
325
226
263
266
169
273
186
Capital expenditures
-85
-68
-88
-103
-143
-107
-121
-112
Proceeds from dispositions of property, plant and equipment
0
1
1
0
6
1
0
0
Payments for acquisitions, net of cash received, and long-term investments
-53
-36
-89
-159
-39
-72
-45
-4
Payments for purchases of intangible assets
-4
-10
-4
0
-2
-1
-15
-1
Payment for purchase of restricted investment
0
0
0
0
0
0
0
-4
Payments for purchases of marketable securities and investments
-78
-148
-240
-509
-681
-387
-206
-294
Proceeds from sales of marketable securities and investments
0
8
4
49
131
290
76
79
Proceeds from maturities of marketable securities and investments
79
79
203
336
327
276
120
171
Restricted cash
0
0
-6
0
0
0
0
0
Net cash (used in) provided by investing activities
-146
-176
-217
-386
-400
1
-191
-167
Long-term borrowings
2
295
425
0
0
0
0
0
Net (payments) borrowings on line-of-credit arrangements and notes payable
-2
-2
-1
-4
0
0
-2
0
Payments on long-term borrowings
-12
-7
-207
-227
-1
-300
0
0
Proceeds from issuance of common stock
13
10
13
14
11
11
15
8
Payments of contingent consideration
0
0
0
0
0
-25
-2
-3
Debt issuance costs on long-term borrowings
0
-3
-4
0
0
0
-1
0
Purchase of treasury stock
0
0
0
0
0
0
0
0
Excess Tax Benefits from Share-based Compensation
5
1
3
3
3
3
1
4
Net cash provided by (used in) financing activities
6
294
229
-214
13
-312
12
9
Effect of foreign exchange rate changes on cash
-9
2
18
5
10
10
-13
16
Net increase (decrease) in cash and cash equivalents
43
445
257
-332
-111
-132
82
44
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Mar 18, 2013 n/a
calculated values,
restated on Mar 18, 2014 n/a
calculated values,
restated on Mar 2, 2015 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Sumo